Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00306618 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma
A Phase 2 study, sponsored by CASI pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT00306618 is a Phase 2 study that has completed, run by CASI pharmaceuticals. The registered enrollment target is 27 participants.
The verdict
NCT00306618, a Phase 2 study, has completed, sponsored by CASI pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
This single-center, open-label, phase 2 study will evaluate the anti-tumor activity, as well as the safety and pharmacokinetics, of Panzem (2-methoxyestradiol, 2ME2) Nanocrystal Colloidal Dispersion (NCD) administered in patients with recurrent glioblastoma multiforme (GBM)
Interventions
- DRUG Panzem Nanocrystal Colloidal Dispersion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2006-01 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00306618
The ClinicalTrials.gov registry entry for NCT00306618 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CASI pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Panzem Nanocrystal Colloidal Dispersion is the first listed.
NCT00306618 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00306618 about?
NCT00306618 is a clinical study titled "Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma". This single-center, open-label, phase 2 study will evaluate the anti-tumor activity, as well as the safety and pharmacokinetics, of Panzem (2-methoxyestradiol, 2ME2) Nanocrystal Colloidal Dispersion (NCD) administered in patients with recurrent glioblastoma multiforme (GBM)
What is the current status of trial NCT00306618?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2006-01. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00306618?
The interventions under investigation include: Panzem Nanocrystal Colloidal Dispersion (DRUG).
Who is sponsoring clinical trial NCT00306618?
This trial is sponsored by CASI pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.